(3beta,25R)-17-Hydroxyspirost-5-en-3-yl alpha-L-arabinofuranosyl-(1->4)-[6-deoxy-alpha-L-mannopyranosyl-(1->3)]-beta-D-glucopyranoside(CAS: 76296-72-5)

The compound falls under the scope of the REACH regulation in the European Union and must comply with the GHS classification. It is also subject to FDA and EPA regulations for use in the United States. Proper handling, storage, and disposal should be in accordance with these guidelines to ensure safety and legal compliance.

Alternatives in synthesis may include other spirostane derivatives or isomers, such as 25R-26,27-epoxy-5 beta-spirostan-3-one, which can serve similar roles in organic synthesis. Common alternative reagents include sodium hydride or lithium aluminum hydride, but careful consideration should be given to reaction conditions and safety.

Research interest in this compound is primarily focused on its potential applications in medicinal chemistry and natural product synthesis. Market trends suggest a growing interest in developing new drug candidates from natural sources, which could drive demand for this compound in the coming years. Emerging studies are exploring its bioactivity and structural modifications.

Waste containing this compound should be collected in appropriate containers and stored under controlled conditions to prevent degradation. For disposal, it is recommended to follow professional waste disposal protocols, including incineration or chemical treatment. Ensure all precautions are taken to protect the environment and human health during the handling and disposal process.